<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Csv>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE311nnn/GSE311211/suppl/GSE311211_RNAseq_MCF7_siKDM5A_Abema_DMSO_rawcounts.csv.gz</Csv><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE311nnn/GSE311211/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311211</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Transcriptomic profiling in MCF7 cells following KDM5A knockdown and treatment with abemaciclib</name><description>The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens. How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood. Here we show that CDK4/6 inhibition induces redistribution of hypo-phosphorylated Rb to promoters and enhancers. While Rb predictably binds to cell cycle gene promoters to repress transcription, at other sites it unexpectedly promotes expression of oestrogen-responsive genes by integrating into oestrogen receptor (ER)-rich transcriptional hubs. CDK4/6 inhibition enhances ER target gene expression in breast cancer cells, patient-derived xenografts, and clinical HR+ breast cancer samples in an Rb-dependent manner. This reprogramming is mediated in part by KDM5A, whose interaction with Rb contributes to gene regulation at these loci. Critically, components of this Rb-driven ER transcriptional program are pro-proliferative. In endocrine-sensitive tumours, this can be neutralised with anti-oestrogen therapy, explaining therapeutic synergy. In endocrine-resistant settings such as ESR1-mutant breast cancer, the program persists, limiting therapeutic efficacy. These findings reframe Rb as a dual-function transcriptional regulator that, while enforcing cell cycle arrest, can also activate programs that counteract its tumour suppressor function.</description><dates><publication>2026/06/29</publication></dates><accession>GSE311211</accession><cross_references><GSM>GSM9321169</GSM><GSM>GSM9321167</GSM><GSM>GSM9321178</GSM><GSM>GSM9321168</GSM><GSM>GSM9321172</GSM><GSM>GSM9321161</GSM><GSM>GSM9321162</GSM><GSM>GSM9321173</GSM><GSM>GSM9321170</GSM><GSM>GSM9321171</GSM><GSM>GSM9321165</GSM><GSM>GSM9321176</GSM><GSM>GSM9321177</GSM><GSM>GSM9321166</GSM><GSM>GSM9321174</GSM><GSM>GSM9321163</GSM><GSM>GSM9321175</GSM><GSM>GSM9321164</GSM><GPL>30173</GPL><GSE>311211</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>